𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Skin tumorigenesis and Ki-ras and Ha-ras mutations in tumors from adult mice exposed in utero to 3′-azido-2′,3′-dideoxythymidine

✍ Scribed by Zhihua Zhang; Bhalchandra A. Diwan; Lucy M. Anderson; Daniel Logsdon; Ofelia A. Olivero; Diana C. Haines; Jerry M. Rice; Stuart H. Yuspa; Miriam C. Poirier

Book ID
101271431
Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
103 KB
Volume
23
Category
Article
ISSN
0899-1987

No coin nor oath required. For personal study only.

✦ Synopsis

This study was designed to evaluate the potential initiating effects of transplacental 3´-azido-2´,3´dideoxythymine (AZT) and the role of ras mutational activation in skin tumors induced in a two-stage mouse skin model. In addition, mouse liver and lung tumors from a transplacental AZT tumorigenicity study reported elsewhere (Olivero et al., J Natl Cancer Inst 89:1602-1608, 1997) were examined for evidence of ras activation. For both tumor studies, pregnant CD-1 mice were given either vehicle or 25 mg of AZT daily on days 12-18 of gestation. In the 1997 study, the offspring were given no further exposure and were killed at 1 yr of age. For the skin tumor study, all mice received twice-weekly topical 12-O-tetradecanoyl-phorbol-13-acetate (TPA) treatment from weeks 5-35; half of the mice had been exposed to AZT in utero. At weeks 16-18, 30, 31, and 34-41, the skin tumor incidences in mice given AZT and TPA were significantly higher than in mice given TPA alone (P ≤ 0.05). At week 41, the average numbers of tumors per mouse were 1.44 ± 0.36 (mean ± standard error of the mean) and 0.57 ± 0.13 for mice given AZT plus TPA and TPA alone, respectively (P = 0.006). Mutagenesis in ras exons I and II was determined by polymerase chain reaction (PCR) and dye-terminator cycling sequencing of PCR products. Ha-ras exon I codons 12 and 13 were mutated in 11 of 19 tumors (58%) from mice given AZT and TPA and in one of 15 tumors (7%) from mice given TPA alone (P = 0.004). The only mutation in Ha-ras codon 12 (four in four tumors examined) was a G→A transition in the second base, and the major mutation in codon 13 (six in seven tumors examined) was a G→T transversion in the second base. In skin tumors, AZT exposure did not increase the number of Ha-ras codon 61 mutations, and no Ki-ras mutations were observed. Analysis of ras mutations in liver and lung tumors from mice exposed to AZT in utero (Olivero et al.,

📜 SIMILAR VOLUMES

K-ras cancer gene mutations in lung tumo
K-ras cancer gene mutations in lung tumors from female Swiss (CD-1) mice exposed transplacentally to 3′-azido-3′-deoxythymidine
✍ Takatoshi Koujitani; Tai-Vu T. Ton; Stephanie A. Lahousse; Hue-Hua L. Hong; Nobu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 353 KB

## Abstract A transplacental carcinogenicity study was conducted by exposing pregnant Swiss (CD‐1) mice to 0, 50, 100, 200, or 300 mg 3′‐azido‐3′‐deoxythymidine (AZT)/kg body weight (BW) daily for the duration of gestation (18–19 days) [National Toxicology Program,2006]. The incidence of alveolar/b

Tissue-specific activating mutations of
Tissue-specific activating mutations of Ha- and Ki-ras oncogenes in skin, lung, and liver tumors induced in mice following transplacental exposure to DMBA
✍ Alexandre Loktionov; Monica Hollstein; Nicole Martel; Dominique Galendo; J. Rica 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 693 KB

## Abstract Transplacental carcinogenesis represents a good model in which to study the involvement of tissue‐specific oncogene activation in carcinogenesis because a single exposure to a carcinogen induces tumors at various sites. We tested tumors of the skin, liver, and lung produced in mice afte